These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26506681)

  • 1. Dosing Medications in Obese Patients.
    Linder KE; Nolan WC
    Conn Med; 2015 Sep; 79(8):487-92. PubMed ID: 26506681
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacotherapy in the critically ill obese patient.
    Medico CJ; Walsh P
    Crit Care Clin; 2010 Oct; 26(4):679-88. PubMed ID: 20970057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antibiotics and overweight].
    Madsen H; Brøsen K; Frimodt-Møller N; Gahrn-Hansen B
    Ugeskr Laeger; 2005 May; 167(21):2266-70. PubMed ID: 15962851
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased enoxaparin dosing is required for obese children.
    Lewis TV; Johnson PN; Nebbia AM; Dunlap M
    Pediatrics; 2011 Mar; 127(3):e787-90. PubMed ID: 21321026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nursing behaviors related to vancomycin and aminoglycoside administration.
    Anderson BC; Crader MF; Nix ES; McDaniel M
    Medsurg Nurs; 2012; 21(6):378-82, 384. PubMed ID: 23477032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
    Bendetowicz AV; Béguin S; Caplain H; Hemker HC
    Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vancomycin trough concentrations in overweight or obese pediatric patients.
    Heble DE; McPherson C; Nelson MP; Hunstad DA
    Pharmacotherapy; 2013 Dec; 33(12):1273-7. PubMed ID: 23798327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Setting up an automatic pharmacist-initiated pharmacokinetic dosing service.
    Ament PW; McGuire WM
    Hosp Formul; 1993 Jun; 28(6):589-92. PubMed ID: 10126587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.
    Davidson BL; Büller HR; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob GE; Segers AE; Lensing AW;
    J Thromb Haemost; 2007 Jun; 5(6):1191-4. PubMed ID: 17403087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
    Mahaffey KW; Tonev ST; Spinler SA; Levine GN; Gallo R; Ducas J; Goodman SG; Antman EM; Becker RC; Langer A; White HD; Aylward PE; Col JJ; Ferguson JJ; Califf RM;
    Int J Cardiol; 2010 Mar; 139(2):123-33. PubMed ID: 19012977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients.
    Bogard KN; Peterson NT; Plumb TJ; Erwin MW; Fuller PD; Olsen KM
    Crit Care Med; 2011 Mar; 39(3):560-70. PubMed ID: 21221000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjusting the dose of low molecular weight heparins in renally impaired and obese patients.
    Spinler S
    Clin Adv Hematol Oncol; 2004 May; 2(5):270, 273-4. PubMed ID: 16163192
    [No Abstract]   [Full Text] [Related]  

  • 13. Individualized compared with conventional dosing of enoxaparin.
    Barras MA; Duffull SB; Atherton JJ; Green B
    Clin Pharmacol Ther; 2008 Jun; 83(6):882-8. PubMed ID: 17928819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin.
    Hermida J; Tutor JC
    Ther Drug Monit; 2006 Jun; 28(3):326-31. PubMed ID: 16778715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity.
    Pai MP; Rodvold KA
    Diagn Microbiol Infect Dis; 2014 Feb; 78(2):178-87. PubMed ID: 24268292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.
    Nunn MO; Corallo CE; Aubron C; Poole S; Dooley MJ; Cheng AC
    Ann Pharmacother; 2011 Jun; 45(6):757-63. PubMed ID: 21652786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Over-dialysis plasma RANTES increase depends on heparin dose and cardiovascular disease status.
    Naumnik B; Koc-Żórawska E; Myśliwiec M
    Adv Med Sci; 2013; 58(2):311-9. PubMed ID: 23959669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers.
    Sanderink GJ; Le Liboux A; Jariwala N; Harding N; Ozoux ML; Shukla U; Montay G; Boutouyrie B; Miro A
    Clin Pharmacol Ther; 2002 Sep; 72(3):308-18. PubMed ID: 12235452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat.
    Daykin HJ; Sturgeon SA; Jones C; Wright CE
    Thromb Res; 2006; 118(6):755-62. PubMed ID: 16410020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosage of enoxaparin among obese and renal impairment patients.
    Bazinet A; Almanric K; Brunet C; Turcotte I; Martineau J; Caron S; Blais N; Lalonde L
    Thromb Res; 2005; 116(1):41-50. PubMed ID: 15850607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.